-6.42%
-13.56%
-28.67%
-29.17%
-60.92%
-89.14%
-92.77%
AI Spotlight on BRNS
Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Market Data
| Last Price | 1.02 |
| Change Percentage | -6.42% |
| Open | 1.05 |
| Previous Close | 1.09 |
| Market Cap ( Millions) | 40 |
| Volume | 34732 |
| Year High | 4.16 |
| Year Low | 0.8 |
| M A 50 | 1.01 |
| M A 200 | 1.45 |
Financial Ratios
| FCF Yield | -136.91% |
| Dividend Yield | 0.00% |
| ROE | -34.39% |
| Debt / Equity | 7.95% |
| Net Debt / EBIDTA | 170.25% |
| Price To Book | 0.25 |
| Price Earnings Ratio | -0.69 |
| Price To FCF | -0.73 |
| Price To sales | 1.98 |
| EV / EBITDA | 0.97 |
News
- Jan -31 - Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
- Jan -10 - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
- Nov -25 - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
- Nov -15 - Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
- Nov -15 - Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
- Nov -06 - Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
- Jun -12 - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
- Jun -06 - Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
- May -13 - Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
- May -04 - Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
- May -01 - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- May -01 - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- Apr -18 - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Apr -18 - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Mar -20 - Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
- Jan -05 - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
- Jan -05 - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
- Dec -21 - New partnership aims to advance vaccine against MERS coronavirus
- Nov -09 - Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Nov -09 - Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Immunotherapies and Vaccines
Expected Growth : 10.5 %
What the company do ?
Immunotherapies and Vaccines from Barinthus Biotherapeutics plc are novel treatments that harness the power of the immune system to fight diseases, including cancer and infectious diseases.
Why we expect these perspectives ?
Barinthus Biotherapeutics plc's Immunotherapies and Vaccines segment growth of 10.5% is driven by increasing adoption of personalized medicine, rising cancer prevalence, and growing demand for innovative treatments. Additionally, advancements in gene editing technologies, collaborations, and strategic partnerships are fueling growth in this segment.
Barinthus Biotherapeutics Plc Products
| Product Range | What is it ? |
|---|---|
| Gene Therapies | Barinthus Biotherapeutics plc develops gene therapies to treat rare genetic disorders, focusing on inherited diseases with high unmet medical needs. |
| RNA-based Therapies | The company develops RNA-based therapies to target specific disease-causing genes, offering a potential cure for genetic diseases. |
| Gene Editing Technologies | Barinthus Biotherapeutics plc develops gene editing technologies to correct genetic mutations, enabling precise and efficient gene correction. |
| Stem Cell Therapies | The company develops stem cell therapies to repair or replace damaged cells, offering a potential cure for various diseases. |
| Vaccine Development | Barinthus Biotherapeutics plc develops vaccines against infectious diseases, utilizing its expertise in gene therapy and RNA-based technologies. |
Barinthus Biotherapeutics plc's Porter Forces
Threat Of Substitutes
The threat of substitutes for Barinthus Biotherapeutics plc is moderate, as there are some alternative treatments available for the diseases the company's products target, but they are not yet widely adopted.
Bargaining Power Of Customers
The bargaining power of customers is low, as the company's products are specialized and there are limited alternative options available.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate, as the company relies on a few key suppliers for raw materials and equipment, but has some flexibility to negotiate prices.
Threat Of New Entrants
The threat of new entrants is high, as the biotechnology industry is rapidly evolving and new companies are emerging with innovative products and technologies.
Intensity Of Rivalry
The intensity of rivalry is high, as the company operates in a highly competitive industry with several established players and new entrants vying for market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.50% |
| Debt Cost | 3.95% |
| Equity Weight | 93.50% |
| Equity Cost | 1.72% |
| WACC | 1.87% |
| Leverage | 6.95% |
Barinthus Biotherapeutics plc : Quality Control
Barinthus Biotherapeutics plc passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| ATRY.MC | Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second … |
| ACIU | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen … |
| RVU.WA | Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with … |
| GNS.L | Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Atrys Health
A-Score
1-Year Total Return ->
🥈
Barinthus Bio
A-Score
1-Year Total Return ->
🥉
Idorsia
A-Score
1-Year Total Return ->
4
AC Immune
A-Score
1-Year Total Return ->
5
Ryvu Therapeutics
A-Score
1-Year Total Return ->
6
